benign hematology: bleeding disorders
TRANSCRIPT
![Page 1: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/1.jpg)
Benign Hematology:Bleeding DisordersRavi Krishnadasan, MD, FACPUniversity of Arizona
![Page 2: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/2.jpg)
1. Identify common algorithms for the evaluation of patients with bleeding disorders including inherited and acquired disorders
2. Discuss current recommendations for the evaluation and treatment of idiopathic thrombocytopenia purpura (ITP)
3. Discuss current recommendations for the evaluation and treatment of patients with von Willebrand disease
4. Outline strategies to reduce the risk of bleeding during surgical procedures for patients with bleeding disorders
Learning Objectives
![Page 3: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/3.jpg)
Dr. Krishnadasan has no potential conflicts of interest.
Financial Disclosure
![Page 4: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/4.jpg)
§ Review of hemostasis§ Workup and laboratory testing§ Primary hemostasis
– von Willebrand disease– Immune thrombocytopenia
§ Secondary hemostasis– Hemophilias– Acquired hemophilia– Lupus anticoagulant
Outline
![Page 5: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/5.jpg)
Primary Hemostasis
Mannucci P. N Engl J Med. 2004;;351:683-694.
![Page 6: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/6.jpg)
Primary Hemostasis (cont)
![Page 7: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/7.jpg)
Primary Hemostasis (cont)
![Page 8: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/8.jpg)
Primary Hemostasis (cont)
![Page 9: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/9.jpg)
Primary Hemostasis (cont)
Formation of Platelet Plug!
![Page 10: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/10.jpg)
Secondary Hemostasis
![Page 11: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/11.jpg)
Secondary Hemostasis
![Page 12: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/12.jpg)
1. Vascular injury exposing collagen and tissue factor2. vWF binds collagen to platelets (GPIb-IX);; collagen also
binds platelets directly3. Platelets adhere;; then release ADP and thromboxane A2,
causing platelet aggregation and plug formation4. Platelets adhere to each other with GPIIb-IIIa
Primary Hemostasis (cont)
![Page 13: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/13.jpg)
§ Megakaryocytes are their progenitor cells in the bone marrow§ Lifespan in peripheral blood 8–10 days§ Normal values between 150K and 400K§ Important in primary hemostasis—form the platelet plug§ Important for secondary hemostasis—provide surface and phospholipid for coagulation cascade
§ Contain granules that are released with activation: ADP,platelet factor 4, factor V
Platelets
American Society of Hematology Self-Assessment Program, Fifth Edition, Chapter 10.
![Page 14: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/14.jpg)
Secondary Hemostasis
![Page 15: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/15.jpg)
§ Normally circulate as zymogens (inactive precursors)§ Vitamin K–dependent factors: II, VII, IX, X
– Also protein C and protein S, which are natural anticoagulants§ Intrinsic and extrinsic pathways§ Ultimately lead to fibrin-stabilizing clot
Coagulation Factors
![Page 16: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/16.jpg)
PT/INR
PTTCoagulation Cascade
![Page 17: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/17.jpg)
Platelet Phospholipids Play Central Role in Blood Coagulation
![Page 18: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/18.jpg)
§ In equilibrium with hemostasis§ Removes fibrin deposits and prevents formationof unnecessary fibrin clots
§ In event that lysis of clot occurs rapidly, could see bleeding;; often delayed
Fibrinolysis
![Page 19: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/19.jpg)
Outline§ Review of hemostasis§ Workup and laboratory testing§ Primary hemostasis
– von Willebrand disease– Immune thrombocytopenia
§ Secondary hemostasis– Hemophilias– Acquired hemophilia– Lupus anticoagulant
![Page 20: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/20.jpg)
History§ Decipher whether pattern is consistent with primaryvs. secondary hemostasis– Or delayed bleeding
§ History of transfusions§ History of procedures§ Family history§ Time/age of onset§ Changes with estrogens, or pregnancy
![Page 21: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/21.jpg)
History: Primary Hemostasis§ Mucocutaneous bleeding (microhemorrhage)
– Gum bleeding– Nose bleeds– Bruising: Spontaneous vs. with trauma
§ VERY subjective– Petechiae– Menorrhagia (How many days? Pads?)– Bleeding history with dental extractions
§ Wisdom teeth
![Page 22: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/22.jpg)
Peter Maslak. ASH Image Bank 2013;;2013-3690. Copyright © 2013 American Society of Hematology.
Petechiae
![Page 23: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/23.jpg)
Petechiae
Vascular-platelet defect§ Petechiae, purpura§ Skin and mucous membrane bleeding§ Spontaneous§ Bleeding immediate, prolonged
Purpura
![Page 24: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/24.jpg)
History: Secondary Hemostasis§ Hemarthrosis (macrohemorrhage)
– Knees/elbows > ankles > shoulders > hips– Early sensation of stiffness, or aura
§ Muscle bleeds– Flexors > extensors (iliopsoas, quads, gastrocnemius)– May require prolonged therapy
§ May also see some bruising
![Page 25: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/25.jpg)
Hemarthrosis (joint bleed)
Iliopsoas bleed
Muscle bleed
![Page 26: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/26.jpg)
Laboratory Testing: Primary Hemostasis
§ Platelet function– Bleeding time– Platelet aggregation– PFA-100– Thromboelastogram (TEG)
**Make sure patient is not on NSAIDs or aspirinand is not thrombocytopenic!!
![Page 27: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/27.jpg)
PFA-100
![Page 28: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/28.jpg)
Laboratory Testing: Primary Hemostasis(cont)§ Von Willebrand
– von Willebrand antigen (vW Ag)– von Willebrand activity
§ Ristocetin cofactor activity– Factor VIII activity
– von Willebrand multimers– Collagen-binding activity– Ristocetin-induced platelet aggregation– Genetic testing
![Page 29: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/29.jpg)
Laboratory Testing: Secondary Hemostasis
§ Prothrombin time (PT)§ Activated partial thromboplastin time (aPTT)§ Mixing study§ Factor activities§ Factor XIII§ Factor inhibitor§ Lupus anticoagulant studies
– DRVVT, anticardiolipin, and antibeta 2 glycoprotein I antibodies
DRVVT = dilute Russell’s viper venom time.
![Page 30: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/30.jpg)
Mixing Study§ Also known as a 1:1 mix§ Two steps
1. Mix patient’s serum with normal serum and measure PT or aPTT2. Incubate sample for 1 hour and recheck PT and aPTT
*This will differentiate a factor deficiency vs. an inhibitor
![Page 31: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/31.jpg)
PT/INR
PTTCoagulation Cascade
![Page 32: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/32.jpg)
Outline§ Review of hemostasis§ Workup and laboratory testing§ Primary hemostasis
– von Willebrand disease– Immune thrombocytopenia
§ Secondary hemostasis– Hemophilias– Acquired hemophilia– Lupus anticoagulant
![Page 33: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/33.jpg)
von Willebrand Disease§ Most common bleeding disorder§ Prevalence of 1/100 to 1/10,000§ Autosomal inheritance: Seen equally in malesand females
§ Involved with both primary and secondary hemostasis
American Society of Hematology Self-Assessment Program, Fifth Edition, Chapter 9.
![Page 34: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/34.jpg)
von Willebrand Disease§ Carrier protein for factor VIII§ So with certain types (IIN, III), may see factorVIII deficiency;; similar clinical presentations
§ But mainly key factor in primary hemostasis withkey interactions with platelets and endothelium,so may see clinical similarities to platelet disorders
![Page 35: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/35.jpg)
Mannucci PM. N Engl J Med. 2004;;351:683-694.
Simplified Model of von Willebrand Factor Functions in Platelet-Plug Formation
![Page 36: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/36.jpg)
Most common, 60%-75%
Rare
Types of von Willebrand Disease
Mannucci PM. N Engl J Med. 2004;;351:683-694.
![Page 37: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/37.jpg)
von Willebrand Disease: Treatment§ DDAVP
– Desmopressin acetate (intranasal)– IV
§ Antifibrinolytic drugs: Aminocaproic acid, tranexamic acid§ Plasma-derived products
– Humate-P– Antihemophilic factor/von Willebrand factor complex [human]– von Willebrand factor, factor VIII complex
§ Oral contraceptive pills
![Page 38: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/38.jpg)
Platelet Disorders§ Thrombocytopenia
– Platelet count less than 150,000/mm3
§ Platelet dysfunction§ Thrombocytosis
– Platelet count greater than 450,000/mm3
– Essential thrombocytosis - ? Bleeding defect
![Page 39: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/39.jpg)
Thrombocytopenia
150,000–400,000/mm3 Normal range> 100,000/mm3 No abnormal bleeding
> 40,000/mm3No spontaneous bleeding;; abnormal bleeding with trauma
< 20,000/mm3 Spontaneous bruising common
< 1,000–5,000/mm3 Severe spontaneous bleeding
Rosdahl CB, et al. Textbook of basic nursing.Philadelphia, PA: Lippincott Williams & Wilkins;; 2008.
![Page 40: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/40.jpg)
Immune Thrombocytopenia§ Presentation§ Definition
– Platelets < 100,000/mm3
– Diagnosis of exclusion– No robust clinical or laboratory parameters are currently available
to establish its diagnosis with accuracy§ Primary vs secondary
Rodeghiero F, et al. Blood. 2009;;113:2386-2393.
![Page 41: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/41.jpg)
Immune Thrombocytopenia (cont)§ Phases of disease
– Newly diagnosed: Within 3 months of diagnosis– Persistent ITP: Between 3 to 12 months from diagnosis – Chronic ITP: Lasting for more than 12 months– Severe ITP: Presence of bleeding symptoms at presentation
sufficient to mandate treatment or occurrence of new bleeding symptoms requiring additional therapeutic intervention
Rodeghiero F, et al. Blood. 2009;;113:2386-2392.
![Page 42: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/42.jpg)
ASH 2011 Evidence-Based Practice Guideline for Immune Thrombocytopenia
Treatment type Initial response, days Peak response, daysAnti-D 1–3 3–7Azathioprine 30–90 30–180Danazol 14–90 28–180Dexamethasone 2–14 4–28Eltrombopag 7–28 14–90IVIg 1–3 2–7Prednisone 4–14 7–28Rituximab 7–56 14–180Romiplostim 5–14 14–60Splenectomy 1–56 7–56Vinblastine 7–14 7–42Vincristine 7–14 7–42
Neunert C, et al. Blood. 2011;;117:4190-4207.
![Page 43: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/43.jpg)
Senile Ecchymosis/Purpura§ Age-related§ Especially on forearms/sun-exposed regions§ Related to sun damage, increased vascular fragility § Worsened by steroids and antiplatelet agents§ Benign: No treatment necessary
![Page 44: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/44.jpg)
Outline§ Review of hemostasis§ Workup and laboratory testing§ Primary hemostasis
– von Willebrand disease– Immune thrombocytopenia
§ Secondary hemostasis– Hemophilias– Acquired hemophilia– Lupus anticoagulant
![Page 45: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/45.jpg)
Hemophilia§ Factor VIII or IX deficiency§ X-linked recessive (males)§ Occasional symptomatic carriers (females)
![Page 46: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/46.jpg)
Hemophilia (cont)
Laboratory defect Clinical manifestation Bleeding symptoms
< 1% Severe Early childhoodspontaneous
1%–5% Moderate Usually only after traumaMay be spontaneous
5%–30% Mild After trauma
https://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia/diagnosis
![Page 47: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/47.jpg)
Hemophilia: Treatment§ Factor replacement§ Fibrinolysis inhibitors: Aminocaproic acid§ Desmopression (DDAVP)§ Bypassing agents
– Activated factor VIIa– FEIBA (activated prothrombin complex concentrate [PCC])
§ On demand vs. prophylaxis
![Page 48: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/48.jpg)
Additional Factor Deficiencies§ Elevated PTT
– Factor XI deficiency– Factor XII deficiency
§ Elevated PT– Factor VII deficiency– Vitamin K deficient (poor nutrition, Abx)
![Page 49: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/49.jpg)
Acquired Hemophilia§ Seen in pregnant females, elderly, patients with autoimmuneor lymphoproliferative diseases;; can also been seen withhepatitis C/interferon therapy
§ Present with significant hematomas and bruising, insteadof joint or muscle bleeds
§ High morbidity and mortality (22%)
Janbain M, et al. J Blood Med. 2015;;6:143-150;; Green D, Lechner K. Thromb Haemost. 1981;;45:200-203.
![Page 50: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/50.jpg)
Acquired Hemophilia (cont)
Janbain M, et al. J Blood Med. 2015;;6:143-150.
![Page 51: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/51.jpg)
Acquired Hemophilia (cont)§ Diagnosis
– Mixing study: Partial correction, then prolongation with 1-hour incubation
– Factor studies: Identify type§ Additional studies
– Inhibitor titer (Bethesda units [BUs])
Janbain M, et al. J Blood Med. 2015;;6:143-150.
![Page 52: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/52.jpg)
Acquired Hemophilia (cont)§ Treatment
– Stop bleeding§ Low titer (< 5 BUs): High-dose factor§ High titer (> 5 BUs): Bypassing agent
– Activated factor VIIa – Prothrombin complex concentrate (PCC): FEIBA– More recently porcine factor VIII
– Suppress antibody production§ Prednisone with or without cyclophosphamide§ Rituximab§ IVIG and other immunosuppressants
Janbain M, et al. J Blood Med. 2015;;6:143-150.
![Page 53: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/53.jpg)
Case StudyA 32-year-old female presents for surgery and is incidentally foundto have an elevated PTT on preoperative labs. The surgeon refers the patient to your clinic on Monday for a surgery that they wouldlike to perform on Friday.
![Page 54: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/54.jpg)
Audience Reponse QuestionWhat is the first step in the evaluation of this patient?
A. von Willebrand studies JL410B. PFA-100 JL411C. A bleeding history JL412D. Mixing study JL413
![Page 55: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/55.jpg)
Questions for the Patient§ Bleeding questions
– Do you have a history of easy bruising or bleeding?– Have you ever had any procedures in the past?– Do you/did you have heavy periods?– Have you ever needed a blood transfusion?
§ Clotting questions– Have you ever had any blood clots, strokes, or heart attacks?– Have you had any miscarriages?
![Page 56: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/56.jpg)
Lupus Anticoagulant§ Clinicopathologic diagnosis
– Clinical: Clotting, miscarriages, thrombocytopenia– Pathologic:
§ Lupus anticoagulant (DRVVT)§ Anticardiolipin antibody§ Antibeta 2 glycoprotein I antibody
§ 12 weeks apart
Lim W. Hematology Am Soc Hematol Educ Program. 2009;;2009:233-239.
![Page 57: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/57.jpg)
Audience Reponse QuestionWhat is the first lab test you would order?
A. von Willebrand studies JL414B. PFA-100 JL415C. Lupus anticoagulant JL416D. Mixing study JL417
![Page 58: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/58.jpg)
Audience Reponse QuestionTest results show partial correction with prolongation. What does this patient have?
A. Lupus anticoagulant JL418B. Factor VIII deficiency JL419C. Factor VIII inhibitor JL420D. Both A and C JL421
![Page 59: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/59.jpg)
Audience Reponse QuestionThe patient never had a history of clotting or bleeding.What is your recommendation for surgery?
A. Observation, with appropriate deep vein thrombosisprophylaxis after surgery JL422
B. Desmopressin acetate JL423C. Factor VIII replacement JL424D. Surgery is bad JL425
![Page 60: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/60.jpg)
Clinical Pearls§ History is most important part of bleeding history§ Primary hemostasis: You see mucocutaneous bleeding
– What are the main components of primary hemostasis?§ Secondary hemostasis: Macro, joints, muscle bleeds§ Most important test in secondary hemostasis for elevatedPT/PTT is mixing study to distinguish deficiency from inhibitor
§ Acquired factor VIII inhibitors: Prolonged PTT, partial correction with prolongation
![Page 61: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/61.jpg)
Primary Hemostasis
Formation of Platelet Plug!
![Page 62: Benign Hematology: Bleeding Disorders](https://reader035.vdocuments.site/reader035/viewer/2022062223/5868be8b1a28ab677d8b59a0/html5/thumbnails/62.jpg)
Secondary Hemostasis